je.st
news
Home
› Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
2014-02-05 07:12:10| drugdiscoveryonline News Articles
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization
Tags: development
focus
programs
preparation
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|